David E. Lazar's Insider Trades & SAST Disclosures
David E. Lazar's most recent trade in LQR House Inc was a trade of 100,000 Common Stock done . Disclosure was reported to the exchange on April 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David E. Lazar.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| LQR House Inc | David E. Lazar | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2025 | 100,000 | 100,000 | - | 0 | Common Stock | |
| Cyclacel Pharmaceuticals Inc | David E. Lazar | Interim CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.03 per share. | 26 Feb 2025 | 194,628,820 | 0 (0%) | 1131% | 0.0 | 5,507,996 | Common Stock |
| Cyclacel Pharmaceuticals Inc | David E. Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 191,978,820 | 194,628,820 (999.99%) | 1116% | - | Common Stock | |
| Cyclacel Pharmaceuticals Inc | David E. Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 2,650,000 | 2,650,000 (15%) | 15% | - | Common Stock | |
| Cyclacel Pharmaceuticals Inc | David E. Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 1,745,262 | 354,738 | - | - | Series D Convertible Preferred Stock | |
| Cyclacel Pharmaceuticals Inc | David E. Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 1,000,000 | 0 | - | - | Series C Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 2,800,000 | 0 | - | - | Warrants | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 2,219,447 | 85,910 | - | - | Series A Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 1,200,000 | 2,681,980 | - | - | Common Stock | |
| Cyclacel Pharmaceuticals Inc | David E. Lazar | Interim CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 2,100,000 | 2,100,000 | - | - | Series D Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.03 per share. | 26 Dec 2024 | 1,456,980 | 1,481,980 | - | 0.0 | 49,974 | Common Stock |
| LQR House Inc | David E. Lazar | Director, President | 21 Nov 2024 | 821,818 | 280,000 | - | - | Common Stock | ||
| LQR House Inc | David E. Lazar | Director, President | 21 Nov 2024 | 280,000 | 0 | - | - | Common Stock | ||
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2024 | 305,357 | 2,305,357 | - | - | Series A Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Jul 2024 | 550,000 | 0 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 23 Apr 2024 | 150,000 | 550,000 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2024 | 150,000 | 550,000 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 100,000 | 100,000 (1%) | 1% | - | Common Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Apr 2024 | 200,000 | 9,600,000 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 200,000 | 200,000 | - | - | Series E Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Jan 2024 | 2,800,000 | 2,800,000 | - | - | Warrants | |
| Minim Inc | Lazar E. David | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 Jan 2024 | 2,000,000 | 2,000,000 | - | - | Series A Convertible Preferred Stock | |
| Minim Inc | David Lazar E. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 25,000 | 25,000 | - | - | Common Stock | |
| Titan Pharmaceuticals, Inc... | David E. Lazar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2023 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Titan Pharmaceuticals, Inc... | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 1.23 per share. | 21 Jun 2023 | 3,388,902 | 0 (0%) | 4% | 1.2 | 4,168,349 | Common Stock, par value $0.001 |
| Titan Pharmaceuticals, Inc... | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 1.23 per share. | 21 Jun 2023 | 359,066 | 0 (0%) | 0% | 1.2 | 441,651 | Common Stock, par value $0.001 |
| Titan Pharmaceuticals, Inc... | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 24 Jan 2023 | 37,500 | 3,368,902 (4%) | 0% | 1.0 | 36,221 | Common Stock, par value $0.001 |
| Titan Pharmaceuticals, Inc... | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 24 Jan 2023 | 20,000 | 3,388,902 (4%) | 0% | 1.0 | 20,066 | Common Stock, par value $0.001 |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges